

Genetic Analysis AS

Simplified disclosure document in relation to secondary offering

2 JUNE 2025

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, THE UNITED KINGDOM, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, SOUTH KOREA, RUSSIA, BELARUS OR IN ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES BEYOND THOSE REQUIRED BY SWEDISH OR NORWEGIAN LAW.

PLEASE SEE THE SECTION ' RESTRICTIONS ON SALES AND TRANSFERS ' AT THE END OF THIS PRESS RELEASE FOR ADDITIONAL INFORMATION ON DISTRIBUTION OF THE OFFER AND THE COMPANY'S FINANCIAL INSTRUMENTS OUTSIDE OF NORWAY AND SWEDEN.

Issuer information	Name: Genetic-Analysis AS (“Genetic Analysis” or the “Company”) Organization number: 993 373 575 LEI-code: 5493004G3I23R6STCD61 Country of registration: Norway Website: www.genetic-analysis.com
Declaration of responsibility	<p>The Board of Directors of Genetic Analysis is responsible for the contents of this document. To the best of the Board of Directors' knowledge, the information given in the document is in accordance with the facts and no information likely to affect them has been omitted. The members of the Board of Directors are presented below.</p> <p>Morten Jurs, Chairman of the Board Camilla Huse Bondesson, Board member Richard Kurtz, Board member Thorvald Steen, Board member Rune Sørum, Board member Ove Öhman, Board member</p>
Authority	<p>This document does not constitute a prospectus under the regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market and repealing Directive 2003/71/EG, as amended (the ‘Prospectus Regulation’). This document has been prepared in accordance with paragraph 4.16 in Spotlight’s regulations regarding simplified information document in connection with secondary issues that do not fall under article 1.4 db of the Prospectus Regulation. The Financial Supervisory Authority of Norway (“Finanstilsynet”), as the national competent authority, has not authorised or reviewed this document. Each investor is invited to make its own judgement as to whether it is appropriate to invest in the Company. This document and any related legal matters shall</p>

	<p>be subject to the exclusive jurisdiction of the Norwegian courts.</p>
<p>Compliance with reporting obligations and published information</p>	<p>The Board of Directors of Genetic Analysis hereby certifies that the Company has complied with its reporting and public disclosure obligations on a continuous basis throughout the period that the Company's securities have been admitted to trading, including Directive 2004/109/EG, where applicable, Regulation (EU) No 596/2014 and, where applicable, Delegated Regulation (EU) 2017/565.</p> <p>The regulated information published by Genetic Analysis pursuant to ongoing disclosure obligations, the Company's latest issuing memorandum as well as its listing prospectus is available at www.genetic-analysis.com.</p> <p>At the time of the Offering Genetic Analysis is not delaying the disclosure of inside information pursuant to Regulation (EU) No 596/2014.</p>
<p>Background, motive and use of funds</p>	<p>On 27 May 2025 the Board of Directors of Genetic Analysis resolved, based on authorization granted by the Annual General Meeting on 19 May 2025, on a rights issue with preferential rights for the Company's existing shareholders of maximum 8 230 545 new shares corresponding to maximum proceeds of approximately NOK 7.1 million (the "Offering"). Genetic Analysis AS, founded in 2008, addresses global health challenges with research-driven, standardized microbiome diagnostics via its CE-marked GA-map® platform, enabling rapid detection of gut dysbiosis and pathogen identification to improve patient care worldwide.</p> <p>Genetic Analysis' vision is to become the preferred company for standardised gut microbiota testing worldwide. Genetic Analysis is committed to helping unlock and restore the human microbiome through its state-of-the-art technology.</p> <p>The Offering is intended to provide the Company with capital to strengthen efforts within sales and marketing of existing products. By increasing sales, Genetic Analysis expects to be in a situation where cash flow from product sales can finance potential further developments of diagnostics tests related to other diseases or condition in addition to the current focus areas.</p> <p>Upon a fully subscribed Offering the Company will receive approximately NOK 7.1 million before deduction of transaction-related costs of approximately NOK 1.0 million. Net proceeds from the Offering will primarily be allocated to the following activities:</p> <ul style="list-style-type: none"> • Strengthening sales and marketing efforts 50% • Working capital 50%

<p>Risks</p>	<p>An investment in Genetic Analysis is associated with several risk factors. The risk factors outlined below are limited to those risks that Genetic Analysis considers to be material and specific to Genetic Analysis's business and securities. The risk factors described below are based on the Company's assessment and information available as of the date of publication of this document.</p> <p>It is not certain that the Company can execute the growth plan</p> <p>During 2023 and 2024 Genetic Analysis have worked to increase sales and market penetration of their diagnostic test products. Even though sales have gradually increased the growth have been slower than previously expected. The plan focuses on increasing sales in core markets by signing up new laboratories to implement the GA dysbiosis test and to initiate additional cooperations with companies that offer microbiome altering drugs and that will need diagnostic tests to measure the effect of the drugs.</p> <p>For the Company to successful execute on the growth plan, Genetic Analysis relies on several key actions as described below.</p> <ul style="list-style-type: none"> • Increasing current business volume with existing laboratories that offer the GA map solution • Implementing the GA map solution with new laboratories within the main markets globally • Positive outcome of the cooperation with Ferring regarding their microbiome altering product. Further implementation of similar agreements with other suppliers of microbiome altering drugs as they are approved by the relevant health authorities. • Continued development of Genetic Analysis' largest research project, the IBD project, resulting in GA Map being widely used as the basis for deciding on treatment of IBD patients <p>There is a risk that one or more of the above actions will not be achieved or will not be completed as planned. In such a case, the growth plan may be delayed or not implemented as the Company foresees.</p> <p>Genetic Analysis is subject to risks related to delays and increased costs in the development of biomarkers</p> <p>Genetic Analysis is subject to risks related to delays and increased costs in the development of biomarkers as it can be difficult to predict the costs of biomarker development with precision in advance. There is also a risk that Genetic Analysis will not be able to start development of biomarkers within the planned time as a result of a missing influx of patients needed</p>
---------------------	--

to conduct studies. There is thus a risk that the planned development of biomarkers will be delayed, which may entail significant costs attributable to the extended research and development time. There is a risk that development will be temporarily halted or that the Company will be forced to conduct operations at a slower pace than desired, which may lead to delayed or non-existent further commercialization and revenues.

Genetic Analysis is subject to risk linked to expansion of the business

Genetic Analysis plans to expand the business in the EU, the US and Asia over the coming years. Establishing and sustaining growth in these markets may involve unpredictable risks. Failure to achieve the planned growth could adversely affect the company's financial position. In addition, too rapid growth can entail organizational challenges. There is a risk that the Company will not be able to recruit sufficiently competent personnel or will fail to integrate new staff into the organization, in which case the business cannot continue to be run in line with the stated direction.

Genetic Analysis is subject to risks related to competition

Genetic Analysis has developed the GA-map® platform, which to the knowledge of the Board is currently the only patented and CE-IVD-marked routine diagnostic tool for the gut microbiota on the market. Since the market for microbiota tests is otherwise characterized by non-standard research-based testing, the Board of Directors and management of the Company assess that there are currently no distinct competitors to Genetic Analysis. There is a risk that more companies will develop similar diagnostic products as Genetic Analysis develops and markets. There is a risk that these will further develop and improve their products so that they more clearly compete with Genetic Analysis. There is a risk that these competitors will succeed in developing more effective diagnostic products than the Company, even though the Company has protected its technology with a number of patents. If a competitive situation arises that makes it difficult for the Company to successfully position itself in the market, it may have a negative impact on the Company's operations, revenue potential and financial position.

Genetic Analysis is subject to regulatory risk

The Company's operations are subject to approvals by relevant regulatory authorities, such as the U.S. Food and Drug Administration ("FDA") and/or the European Medicines Agency ("EMA"). In order to obtain the right to market and sell the Company's diagnostic products, the products must

undergo an extensive registration procedure with the relevant authority in an individual market. The registration procedure includes, for example, where applicable, requirements relating to development, testing, registration, approval, labelling, manufacturing and distribution. There is a risk that delayed or non-approval may result in requirements for adaptation. If such requirements, which exist or that may be added in the future, are not met, this may entail, for example, the recall of products, a ban on imports, the non-registration being allowed, the withdrawal of previously approved applications, the need for costly development work to be redone or the initiation of prosecution. If the Company is unable to continue its commercialization strategy due to a lack of approval or significant delay, it may lead to a reduced earning capacity of the Company's products.

Genetic Analysis is subject to risks related to intellectual property rights

Genetic Analysis has obtained and applied for additional patents. The Company has pending patent applications, which would adversely affect Genetic Analysis' operations and financial position if the patents are not granted. Patents and intellectual property rights have a limited lifespan. There is a risk that the current and/or future patent portfolio and other intellectual property rights held by the Company will not have full commercial protection. In the event that Genetic Analysis is required to defend its patent rights against a competitor, it may incur substantial costs that could negatively impact the Company's operations, operating results, and financial position. There is a risk that Genetic Analysis violates or infringes on patents from third parties. There is also a risk that other parties' patents may limit the ability or opportunities for one or more of the Company's future partners to freely use the diagnostic product in question. It is not possible to predict the outcome of patent litigation in advance, and there is a risk that an unfavourable outcome of litigation or litigation over intellectual property rights will lead to loss of protection, a prohibition on continuing to use the rights at the time of issue, or an obligation to pay compensatory damages will arise. In addition, such disputes are costly, even in the event of an end result with a favourable outcome for the Company. There is a risk that this will negatively affect Genetic Analysis' results and financial situation. There is a risk that the above will lead to difficulties or delays in the commercialization of future products and thus difficulties in generating revenue.

Genetic Analysis is subject to risks related to financing

Genetic Analysis is now executing its growth plan with the aim of increasing the Company's commercialization and revenues.

It cannot be excluded that the Company will be in need of additional financing, through borrowing or equity, to cover future capital needs. Nor is there any guarantee that such other financing can be obtained on satisfactory terms, or to a sufficient extent to finance the activities in accordance with established development plans and objectives. Since the question of whether and when the Company may issue securities in the future is dependent on future market conditions, the Company cannot predict or estimate the amount, timing or nature of such offer. Therefore, shareholders bear the risk that future offerings reduce the market price of the shares and/or dilute their shareholding.

Genetic Analysis is subject to risks related to sales and earning capacity

It cannot be stated with certainty that the products sold by the Company will have the market impact as expected by the Company. If the Company fails to generate profits to a sufficient extent, the Company's results and financial position risk being adversely affected.

Genetic Analysis is subject to valuation of intangible non-current assets

Genetic Analysis's intangible assets are valued at approximately NOK 15 million as of 31 March 2025. This amount is linked to the development of own products for commercial sale and is capitalized in accordance with IFRS/IAS 38. These are four intangible facilities, all of which help lay the foundation for the current technology platform "GA-map Dysbiosis Test". These are mainly depreciated over 10 years and impairment tests are performed quarterly and reviewed by the auditor annually. Genetic Analysis activates wage costs and material costs that have been included in the development projects together with purchased goods and services (e.g. if help is needed in connection with advanced software and algorithm development/implementation). The Company is doing this in accordance with IFRS rules for capitalization of development costs. Reviews/write-downs are carried out based on an NPV calculation based on future plans for the business. In addition, commercial assessments are made of whether a development is marketable in accordance with market development and achieved sales results. There is a risk associated with whether these facilities are overvalued or should have been depreciated more. If the sale of GA-map will deviate significantly negatively from sales plans, there is a risk associated with the valuation of the fixed assets. The Board of Directors and management believe that all current intangible assets have a long-term horizon and that a ten-year depreciation period is prudent.

Genetic Analysis is subject to risk related to currency fluctuations and trade development

Exceptional external factors such as inflation, currency and interest rate changes, supply and demand, government-imposed trade restrictions, in the form of custom duties, tariffs or by other means as well as recessions and booms can have an impact on operating costs and sales prices. Genetic Analysis can also be negatively affected by global or regional events such as pandemics, wars, extreme weather or other events that disturbs normal flow of commercial trade. Genetic Analysis' future revenues may be adversely affected by these factors, which are beyond the Company's control.

Genetic Analysis is subject to risk related to adherence to current and future GDPR requirements

As part of performing GA's service lab activities, Genetic Analysis receives patient samples for analysis in the Company's service lab, either as normal samples submitted by physicians/specialists (I) or as clinical research samples (II) where patients are included as part of a study. Patient samples from clinical studies are normally blinded and Genetic Analysis works with only one sample ID number. When receiving samples from doctors/specialists, Genetic Analysis also handles potential patient-sensitive data. Handling of patient data is always done with the utmost care, and Genetic Analysis has strict rules and procedures for how this data is handled. All samples are given a sample ID number and the data is processed and managed in offline systems. The results reports are encrypted when sent from Genetic Analysis. Genetic Analysis has standard operating procedures in place to ensure that patient-sensitive data is kept secure and deleted when it is no longer needed. Genetic Analysis continuously evaluates the Company's procedures and practices in accordance with GDPR. The Company's measures to maintain the security and integrity of sensitive data, such as patient data, there is a risk that the Company's security measures regarding systems and other security procedures, do not prevent unauthorized intrusion, that personal data or protected information is disclosed, or can otherwise be considered to be associated with deficiencies. This could damage the Company's reputation and result in the Company being liable for damages, and thus result in increased costs and/or reduced revenues. If any of these events were to occur, it could have a negative effect on the Company's operations, profitability and financial position.

Genetic Analysis is dependent upon a limited number of key personnel

Genetic Analysis' future is highly dependent on the knowledge, experience and commitment of the company's management. At the date of this information document, the Company's management consists of four people, Ronny Hermansen, Christina Casén, Kari Furu and Lars Tiller with significant knowledge of GA-map® and the Company's overall operations. The Genetic Analysis organization is fragile in the event that one or more of these individuals should terminate their involvement in the Company. There is a risk that the Company will not be able to retain these key employees and that the Company will fail to recruit qualified people in the future. New recruitments can also take a long time to complete. If one or more key employees terminate their involvement in the Company, this may mean that the Company loses extensive knowledge of the business, treatment and development work. In a scenario where one or more key employees leave Genetic Analysis, the Company may be forced to pursue the growth plan and further commercialization at a slower pace.

Risks related to the development of the share price

There are no guarantees that the share price in Genetic Analysis will have a positive development and there is a risk that investors in the Company – in whole or in part – will not receive back invested capital. If the Company's growth plan is delayed or does not reach the targets, the Company's share price may decline significantly. Furthermore, Genetic Analysis' share price may be adversely affected by such factors as interest rate increases, political events, exchange rate changes and deteriorating economic conditions, which the Company is unable to influence. There is a risk that the Company's share price may fluctuate significantly, mainly as a result of how the growth plan and further commercialization are achieved. The Company's share price may be subject to extreme price and volume fluctuations that are not related to, or proportionate to, the operating outcome of the Company. Genetic Analysis' stock could fall sharply in value. An investor may thus lose all or part of his invested capital in the Company. In the event of a non-dividend, the shareholder's return in Genetic Analysis will only depend on the share price development.

Risks related to the liquidity of the share

The Company's shares are admitted to trading on Spotlight. Trading in the Company's shares may in the future be inactive and illiquid, which in turn may cause difficulties for holders to dispose of shares, quickly or at all. An investor who wishes to sell his or her holding in the Company may need to sell shares at a significant loss.

	<p>Risks related to future sale of shares</p> <p>Genetic Analysis' largest shareholder – Bio-Rad Laboratories Inc. (owned via Citibank, N.A.) – holds approximately 23 percent of the votes and capital in the Company as of the date of this information document. In addition, members of both the Board of Directors and management hold shares in Genetic Analysis. There is thus a risk that Genetic Analysis' share price will decrease significantly if there is extensive sale of shares in the Company, especially if such sale is carried out by board members, senior executives or major shareholders, which in turn could have a negative impact on the Company's share price. In the event that a sale is carried out by one or more shareholding board members, major shareholders and/or senior executives, it may have a significant impact on the share price development.</p>
<p>Name and ISIN code of the security</p>	<p>Share Trading symbol (ticker): GEAN ISIN code: NO0010692130</p> <p>Subscription right Trading symbol (ticker): GEAN TR ISIN code: NO0013577692</p>
<p>Dilution</p>	<p>Upon fully subscribed Offering the number of shares in Genetic Analysis will increase with 8 230 545 new shares from 64 273 847 to 72 504 392.</p> <p>The maximum dilutive effect for the shareholders who choose not to participate in the Offering amounts to approximately 11 percent of the shares and votes (calculated by dividing the maximum number of new shares through the Offering with the total number of shares in the Company after a fully subscribed Offering). Shareholders who do not participate in the Offering can partially compensate themselves for the financial dilution effect by selling their subscription rights no later than 12 June 2025.</p>
<p>Terms for the offering</p>	<p>TERMS AND CONDITIONS OF THE OFFERING</p> <p>The Offering and Subscription Rights</p> <p>In accordance with the shareholders' pre-emptive subscription right, Genetic Analysis AS ("Genetic Analysis" or the "Company") is offering up to 8 230 545 new shares in the Company for subscription (the "Offer Shares") (the "Offering"). The shares in the Offering is ordinary shares with quota value of NOK 0.60 per share.</p> <p>Subscription Rights</p>

Genetic Analysis will give all shareholders registered in Genetic Analysis AS's shareholder register maintained by Euronext Securities Oslo ("Euronext Oslo") one (1) book-entry subscription right (the "Subscription Right") per each share held on the Offering record date 4 June 2025 (the "Record Date"). Six (6) Subscription Right entitles the holder to subscribe for one (1) Offer Share. The Subscription Rights will be registered in shareholders' book-entry accounts in the book-entry system maintained by Euronext Oslo approximately on 5 June 2025 and in the book-entry system maintained by Euronext Oslo approximately on 5 June 2025. The Subscription Rights registered in Euronext Oslo can be freely assigned and they will be traded on Spotlight Stock Market ("Spotlight") (trading symbol GEAN TR), ISIN: NO0013577693 between 5 June 2025 and 12 June 2025. If a Company share entitling to a Subscription Right is subject to a pledge or another such restriction, the Subscription Right may not be exercisable without the consent of the pledgee or other rights holder.

Unexercised Subscription Rights will expire and have no value when the Subscription Period ends.

Please see the section "Restrictions on Sales and Transfers" below for a description of certain restrictions and prohibitions that apply to the exercise of subscription rights in certain jurisdictions.

The right to subscribe for unsubscribed Offer Shares without Subscription Rights

The Board of Directors of the Company shall resolve on offering any unsubscribed Offer Shares secondarily to shareholders and other investors who have submitted a subscription application concerning the Offer Shares during the Subscription Period without Subscription Rights. See subsequently "*Subscription for Offer Shares without Subscription Rights and allocation*".

Underwriting commitments

The offering is not underwritten and there is a risk that the offering is not fully subscribed

Subscription Price

Subscription Price of Offer Shares is NOK 0.86 per Offer Share (the "Subscription Price"). The Subscription Price has been set to the same as the subscription price in the Company's directed issue, as announced on 5 May 2025. The subscription price in the directed issue was based on the volume weighted average share price for shares traded at Spotlight Market in

the period from and including 21 March 2025 to and including 24 April 2025.

Subscription Period

The subscription period for the Offer Shares (the “Subscription Period”) will commence on 2 June 2025 at 9.00 CET and is expected to end on 16 June 2025 at 12.00 CET.

The Board of Directors may, at its sole discretion, extend the Subscription Period. The Subscription Period may be extended once or several times, however not past 25 June 2025. Any extensions of the Subscription Period will be announced by way of a press release before the end of the Subscription Period.

If the Subscription Period is extended, the allocation date, the payment due dates and the dates of delivery of Offer Shares will be changed accordingly.

Subscription locations, account operators, custodians and nominees may require their customers to submit subscription orders on a certain day prior to the end of trading on the Subscription Rights or before the Subscription Period ends.

Subscription via financial intermediaries

A shareholder may participate in the Offering by subscribing for the Offer Shares by using the Subscription Rights on the shareholder’s book-entry account and by paying the Subscription Price. To participate in the Offering, a shareholder shall make a subscription order in accordance with the instructions given by the shareholder’s custodian bank, broker or account operator (“Financial Intermediary”).

The holders of purchased Subscription Rights shall submit their subscription order according to the instructions issued by their Financial Intermediary where the purchased Subscription Rights are held.

Such shareholders and other investors participating in the Offering whose Company shares, or the Subscription Rights are registered in the name of a nominee shall submit their subscription order according to the instructions given by their nominee. The financial intermediary will be responsible for collecting utilization instructions from eligible shareholders and for informing DNB of their utilization instructions. Any questions related to the practical procedure on how to participate in the Offering shall be forwarded to the relevant Financial Intermediary.

Subscription orders must be submitted separately for each book-entry account.

Payments for subscription via financial intermediaries

Each eligible shareholder or other subscriber holding subscription rights through a financial intermediary must pay the subscription price for the offered shares allocated to them in accordance with the instructions provided by the financial intermediary.

The financial intermediary is responsible for making the payment of the subscription price in accordance with the instructions set out in the information document. Payment by the financial intermediary for the shares offered must be made to DNB no later than the settlement date (as defined below). As a result, financial intermediaries may require payment to be provided to them prior to the settlement date.

Deficient or erroneous subscription orders may be rejected. If the Subscription Price is not paid according to these terms and conditions or the payment is insufficient, the subscription order may be rejected. In such a situation, the Subscription Price will be refunded to the subscriber approximately three (3) local banking days from the date when the Board of Directors of the Company has decided on the allocation of the Offer Shares. No interest will be paid for such payment.

Any subscriptions made are binding, and they cannot be changed or cancelled.

Payment method

Each eligible shareholder or other subscriber who holds their subscription rights through a financial intermediary shall pay the subscription price for the offered shares allotted to him in accordance with the instructions received from the financial intermediary.

The financial intermediary shall pay the subscription price in accordance with the instructions in the information memorandum. Payment of the financial intermediary for the shares in the Offer must be made to DNB no later than the settlement date (as set out below). Consequently, financial intermediaries may require payment to be provided to them before the settlement date.

Subscribers who have a Norwegian VPS account

Subscribers who have a Norwegian VPS account must and will, by signing the application form or by submitting the

application form for subscription online for subscription via Euronext Securities Oslo's online subscription system, give the issuing agent a one-time irrevocable authorisation to debit a specified bank account in a Norwegian bank for the amount to be paid for the shares allocated to the subscriber. The specified bank account is expected to be debited on or after the settlement date. The Issuing Agent is only authorized to debit such account once but reserves the right to make up to three debit attempts, and the authorization will be valid for up to seven business days after the settlement date. The subscriber further instructs the issuing agent to obtain confirmation from the subscriber's bank that the subscriber has the right to dispose of the specified account and that sufficient funds are in the account to cover the payment. If there are not sufficient funds in the subscriber's bank account or if it is otherwise not possible to debit such a bank account when an attempted debit is made on the basis of the subscriber's power of attorney, the subscriber's obligation to pay for the shares will be deemed to be due for payment.

Payment by direct debit is a service provided by banks in Norway in cooperation. In the relationship between the subscriber and the subscriber's bank, the standard terms and conditions for "Payment by direct debit - securities trading", as set out on page 2 of the application form, will apply, with the proviso that subscribers who subscribe for an amount in excess of NOK 5 million must make a manual payment to the issuing agent. The Issuing Agent will provide additional details for payment to such subscribers after the end of the subscription period and allotment of shares.

Subscribers who do not have a Norwegian bank account

Subscribers who do not have a Norwegian bank account and not subscribing through intermediaries must ensure that payment with settled funds for the shares allotted to them takes place on or before the settlement date. Before any such payment is made, the subscriber must contact DNB as issuing agent for further information and instructions.

Subscription for Offer Shares without Subscription Rights and allocation

The subscription of the Offer Shares without the Subscription Rights by a shareholder and/or another investor is performed by submitting a subscription order to DNB and by paying the Subscription Price no later than 26 June 2025 at the latest, or in accordance with the instructions provided by the subscriber's Financial Intermediary.

A subscription order which is sent by mail has to be submitted in good time before the last day for subscription. An incomplete or incorrect subscription order may be ignored.

The subscription order is binding.

If all the Offer Shares have not been subscribed on the basis of the Subscription Rights, Genetic Analysis' Board of Directors will decide on the allocation of the Offer Shares subscribed for without the Subscription Rights as follows:

- a) First to those who also have subscribed for the Offer Shares on the basis of the Subscription Rights. If the subscribers in question oversubscribe the Offering, the allocation to such subscribers will be determined in a book-entry account specific manner in proportion to the number of the Subscription Rights used for the subscription for the Offer Shares and, if this is not possible, by drawing lots; and
- b) Secondly to those who have subscribed for the Offer Shares only without the Subscription Rights, and if the subscribers in question oversubscribe the Offering, the allocation to such subscribers will be determined in a book-entry account-specific manner in proportion to the number of the Offer Shares which the subscribers have subscribed for and, if this is not possible, by drawing lots; and

Genetic Analysis will confirm the approval of the subscription of the Offer Shares subscribed for without the Subscription Rights, if approved, for all investors who have submitted a subscription order to subscribe for the Offer Shares without the Subscription Rights. Investors who subscribe for the Offer Shares without Subscription Rights through their account operators receive information regarding their subscription according to the routines of the account operator.

If the Offer Shares subscribed for without the Subscription Rights are not allocated in the number referred to in the subscription order, the paid Subscription Price corresponding to the Offer Shares not obtained will be refunded to the subscriber approximately on 21 June 2025. No interest will be paid on such a payment.

Approval and payment of subscriptions

The Company's Board of Directors will approve all the subscriptions made on the basis of the Subscription Rights and in accordance with the terms and conditions of this Offering and the applicable laws and regulations approximately on 18 June 2025. In addition, the Company's

Board of Directors will approve the subscriptions made without the Subscription Rights and in accordance with the terms and conditions of the Offering applicable laws and regulations pursuant to the allocation principles presented above in the section “Subscription for Offer Shares without Subscription Rights and allocation”. The Board of Directors may, based on its own consideration, resolve to reject a subscription made by an investor in the Offering inter alia,

- a) If the Board of Directors considers that the subscription breaches an applicable law or regulation; or
- b) there is reason to believe that it would require other measures from the Company than publication of this information document.

The Subscription Price of the Offer Shares subscribed for in the Offering must be paid in full in NOK in Norway. The Subscription Price of the Offer Shares subscribed for in the Offering based on the Subscription Rights must be paid in connection with the submission of the subscription order according to the instructions given by the subscription location, the custodian or the account operator. For payment of subscriptions of the Offer Shares without the Subscription Rights, please see section “*Subscription for Offer Shares without Subscription Rights and allocation*” above. The Board of Directors may, at its sole discretion, extend the payment period.

By subscribing, the subscriber authorizes his / her account operator to disclose the necessary personal data, the number of his / her book-entry account and the details of the subscription to the parties involved in the order or the execution of the order to allocate and settle the Offer Shares.

Announcement of outcome of the Offering

Provided that no changes are made to the Subscription Period, the Company will announce the outcome of the Offering approximately on 18 June 2025 by way of a press release.

Registration and delivery of the Offer Shares

The Offer Shares subscribed for in the Offering will be issued as book entries in the book entry system of Euronext in Oslo and delivered to the investors through the book-entry systems of Euronext Oslo. The delivery and combination will take place approximately on 26 June 2025, in the book-entry system maintained by Euronext Oslo,

	<p>The Offer Shares subscribed for without the Subscription Rights will be delivered at the same time as the ones that have been subscribed for with the Subscription Rights.</p> <p>Shares in the Offer will not be tradeable until registration of the share capital increase in the Norwegian Business Register (NO. Foretaksregisteret) and the Offer shares have been delivered. Accordingly, allotment, registration and trading will not take place in any interim instrument with the equivalence of the Swedish “paid subscribed shares” (so called “BTA”).</p> <p>Shareholder rights</p> <p>The Offer Shares will confer all shareholder rights from their registration with the Trade Register and delivery to the investors. Each Share in the Company confers one vote at the Company's General Meetings.</p> <p>Governing law</p> <p>The Offering and the Offer Shares shall be governed by Norwegian law. The courts of Norway have exclusive jurisdiction to settle any dispute which may arise out of or in connection with the Offering.</p> <p>Other matters</p> <p>The Company’s Board of Directors may make decisions on other matters related to the Offering.</p>
<p>Restrictions on Sales and Transfers</p>	<p>Restrictions on sales and transfers of subscription rights and the issuance of shares in the Offer through the exercise of subscription rights to persons resident in or citizens of countries other than Norway or Sweden may be affected by the laws of the relevant jurisdiction. The Company's shares, including the shares in the Offer, and the subscription rights may in certain jurisdictions be subject to transferability and resale restrictions and may not be transferred or resold except as permitted under applicable securities laws and regulations. Failure to comply with these restrictions may constitute a violation of the securities laws of such jurisdiction.</p> <p>The Company is not taking any measures to permit an offering of the subscription rights or shares in the Offering in jurisdictions other than Norway and Sweden. This information document does not constitute an offer in those jurisdictions in which it would be unlawful to make an offer, and, in such circumstances, this information document is for informational purposes only and should not be copied or redistributed. If an investor receives a copy of this information document in any jurisdiction other than Sweden or Norway, the investor may</p>

not treat this information document as an invitation or offer to him, and the investor may not under any circumstances trade in the Company's shares (including the shares in the Offering) or subscription rights, unless, otherwise stated in this information memorandum, such invitation or offer may lawfully be made to the investor in the relevant jurisdiction, or the shares (including the shares in the Offer) or subscription rights may lawfully be traded without prejudice to any unfulfilled registration requirements or other legal requirements. Accordingly, if an investor receives a copy of this information document, the investor shall not distribute or send the same or transfer the Company's shares (including the shares in the Offer) or subscription rights, to any person or in or to any jurisdiction where this would or may be in conflict with local securities laws or regulations.

Neither the Company nor the issuing agent, nor any of their respective representatives or advisors, makes any representation to any recipient or purchaser of shares in the Offering regarding the legality of an investment in the subscription rights or shares in the Offering by such recipient or purchaser under the laws applicable to such recipient or purchaser. Each investor should consult with their own advisors about the legal, tax, business, financial, and related aspects of a stock purchase.

The information in this section "Restrictions on Sale and Transfer" is intended as a general guide only. If you are unsure about any of the contents of the applicable restrictions, or if any of these restrictions apply to you, you should seek independent professional advice without delay.

United States

The subscription rights and shares in the Offer have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") and may not be offered, sold, exercised, resold, delivered or transferred, directly or indirectly, within the United States, except pursuant to an applicable exemption from the registration requirements of the U.S. Securities Act and in accordance with the securities laws of any state or other jurisdiction of the United States. Any person to whom shares are offered or sold by the Company in the United States, through its subscription of shares, will be invited to provide additional representations and warranties provided by the Company upon request.

Other Jurisdictions

The subscription rights and shares in the Offer have not been and will not be registered under the applicable securities laws of Australia, Canada, Japan, New Zealand, South Africa, Hong Kong, Singapore, South Korea, Russia, Belarus and may not be

	<p>offered, sold, exercised, resold, delivered or transferred, directly or indirectly, in or into Australia, Japan, Canada, New Zealand, South Africa, Hong Kong, Switzerland, Singapore, South Korea, Russia, Belarus or any other jurisdiction in which it would not be permitted to offer the shares in the Offer.</p>
Spotlight Stock Market	<p>The Company's shares are traded on Spotlight Stock Market AB ("Spotlight"). Spotlight is a securities company under supervision of the Swedish Financial Supervisory Authority. Spotlight operates a so-called MTF platform. Companies listed on Spotlight have undertaken to comply with Spotlight's listing agreement. The agreement aims, among other things, to ensure that shareholders and other market participants receive accurate, immediate and simultaneous information about all circumstances that may affect the company's share price. Companies whose shares are traded on Spotlight are not subject to all the legal rules that apply to a company listed on a so-called regulated market. Through its regulatory framework, Spotlight has chosen to apply most of these legal rules. Trading on Spotlight takes place in an electronic trading system that is accessible to the banks and stockbrokers connected to Spotlight Stock Market. This means that anyone wishing to buy or sell shares listed on Spotlight can use their usual bank or stockbroker. The listing agreement and share prices can be found on Spotlight's website (www.spotlightstockmarket.com).</p>